Michmerhuizen, A. R., Chandler, B., Olsen, E., Wilder-Romans, K., Moubadder, L., Liu, M., . . . Speers, C. (2020). Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front Endocrinol (Lausanne).
シカゴスタイル引用形Michmerhuizen, Anna R., et al. "Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells." Front Endocrinol (Lausanne) 2020.
MLA引用形式Michmerhuizen, Anna R., et al. "Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells." Front Endocrinol (Lausanne) 2020.
警告: この引用は必ずしも正確ではありません.